Lasa Supergenerics Ltd
LASALasa Supergenerics Ltd
LASA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -7.17 | 1.45 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Lasa Supergenerics Limited is engaged in the manufacturing of anthelmintics/veterinary active pharmaceutical ingredient (API). The Company also manufactures bulk drugs
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 200.92 | 246.94 | 170.04 | 167.49 | 202.44 | 137.40 | 131.37 | 104.44 | 104.71 | ||||||||||
Raw Materials | 0.00 | 141.67 | 172.06 | 126.21 | 87.01 | 102.11 | 94.46 | 110.12 | 79.28 | 113.48 | ||||||||||
| Power & Fuel Cost | 6.03 | 6.64 | 6.71 | 7.92 | 8.06 | 7.06 | 7.72 | 7.45 | ||||||||||||
| Employee Cost | 9.55 | 10.27 | 11.74 | 13.42 | 14.01 | 7.15 | 6.35 | 5.37 | ||||||||||||
| Selling & Administrative Expenses | 2.24 | 4.45 | 4.65 | 6.54 | 9.72 | 9.03 | 6.98 | 5.64 | ||||||||||||
| Operating & Other expenses | 19.93 | 8.78 | 9.15 | 22.41 | 21.16 | 11.26 | 24.85 | 13.15 | ||||||||||||
EBITDA | 0.00 | 21.50 | 44.74 | 11.58 | 30.19 | 47.38 | 8.44 | -24.65 | -6.45 | -8.77 | ||||||||||
| Depreciation/Amortization | 0.00 | 7.69 | 18.17 | 19.31 | 17.34 | 15.82 | 14.51 | 13.42 | 10.67 | 10.81 | ||||||||||
| PBIT | 0.00 | 13.81 | 26.57 | -7.73 | 12.85 | 31.56 | -6.07 | -38.07 | -17.12 | -19.58 | ||||||||||
| Interest & Other Items | 0.00 | 11.68 | 11.35 | 8.38 | 8.12 | 2.06 | 0.06 | 4.19 | 1.99 | 2.43 | ||||||||||
| PBT | 0.00 | 2.13 | 15.22 | -16.11 | 4.73 | 29.50 | -6.13 | -42.26 | -19.11 | -22.01 | ||||||||||
| Taxes & Other Items | 0.00 | -0.22 | 2.89 | -4.07 | 1.11 | 6.72 | -0.81 | -3.65 | 2.62 | -2.50 | ||||||||||
| Net Income | 0.00 | 2.35 | 12.33 | -12.04 | 3.62 | 22.78 | -5.32 | -38.61 | -21.73 | -19.51 | ||||||||||
| EPS | 0.00 | 470.00 | 10.76 | -5.27 | 1.14 | 5.60 | -1.17 | -7.71 | -4.34 | -3.89 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.25 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | — | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Lasa Supergenerics Ltd | -6.44 | 1.45 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare LASA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 16, 2022
Dividend/Share
₹0.25
Ex DateEx Date
Sep 16, 2022
Cash Dividend
Ex DateEx DateSep 15, 2021
Dividend/Share
₹0.25
Ex DateEx Date
Sep 15, 2021
Lasa Supergenerics announced that the 9th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net Loss of Lasa Supergenerics reported to Rs 2.73 crore in the quarter ended June 2024 as against net loss of Rs 4.95 crore during the previous quarter ended June 2023. Sales rose 0.92% to Rs 30.84 crore in the quarter ended June 2024 as against Rs 30.56 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales30.8430.56 1 OPM %5.8413.25 - PBDT0.933.68 -75 PBT-1.861.03 PL NP-2.73-4.95 45 Powered by Capital Market - Live
Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Lasa Supergenerics reports standalone net loss of Rs 6.61 crore in the September 2022 quarter
Lasa Supergenerics Ltd leads gainers in ‘B’ group
Wardwizard Innovations & Mobility Ltd PartlyPaidup leads gainers in ‘B’ group
Stocks that will see action on April 27, 2022
Lasa Supergenerics standalone net profit rises 223.16% in the March 2022 quarter
Lasa Supergenerics soars after stellar Q4 performance
Lasa Supergenerics logs 362% sequential growth in PAT in Q4FY22; stock skyrockets ~15%
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -9.29%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.08% to 0.03%